Hacker News Board Hacker News, browsed like a classic message board
Live data from Hacker News

Oxford University breakthrough on global COVID-19 vaccine

ox.ac.uk

Post reply on HN
Print view View original

21–30 of 569 posts

Re: Oxford University breakthrough on global COVID-19 vaccine

#21

Post by threeseed »

camkego wrote: post #16

This statement seems a big deal: "There were no hospitalised or severe cases in anyone who received the vaccine" Is that also true of the Pfizer and Moderna trials? Are the various trials measuring 'effectiveness' in the same way? Is there a standard for 'effectiveness' in these Covid-19 trials? It will take some digging and real effort to compare the risks and benefits of the various vaccines coming to market.

There were no hospitalisations or severe incidents for either the Pfizer and Moderna trials were was related to the vaccine.

And it's pretty easy to compare the vaccines. It will mostly come down to price, ease of manufacture and ease of distribution i.e. temperature. Given that for the 3 viruses all have no risks associated with their use.

Re: Oxford University breakthrough on global COVID-19 vaccine

#23

Post by m12k »

"There were no hospitalised or severe cases in anyone who received the vaccine"

Does anyone know if there's data for this and the other vaccines, whether any of those that still end up infected under the trials have had any of the secondary symptoms such as missing sense of smell, reduced cognitive function, reduced bio-motor functions, cardiac damage and so on? Not dying from a lung infection is obviously the most important, but some of the other organ damage that corona-virus can cause is pretty scary too, and I'd like to know whether the vaccines seem to prevent this too.

Re: Oxford University breakthrough on global COVID-19 vaccine

#24

Post by shoo »

jpxw wrote: post #12

From AstraZeneca: > One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significa…

One thing that isn't obvious to me is exactly how `n` is defined, and how that relates to how many people of that `n` were infected by covid during the trial. E.g. maybe n=2,741 people were vaccinated following the first dosing protocol, but perhaps only a small fraction were infected with covid. So the actual sample sizes being used to estimate the efficacy of each dosing protocol may be smaller.

Re: Oxford University breakthrough on global COVID-19 vaccine

#25

Post by rpedela »

2Gkashmiri wrote: post #7

over 7 billion human population, a 90% effectiveness is what? alright? please enlighten me. does anyone know what was the effectiveness of the smallpox vaccine that we did actually manage to eradicate successfully?

> One dose of MMR vaccine is 93% effective against measles, 78% effective against mumps, and 97% effective against rubella. Two doses of MMR vaccine are 97% effective against measles and 88% effective against mumps. MMR is an attenuated (weakened) live virus vaccine.

From:

https://www.cdc.gov/vaccines/vpd/mmr/public/index.html#:~:te....

Re: Oxford University breakthrough on global COVID-19 vaccine

#26

Post by athriren »

crx07 wrote: post #14
jpxw wrote: post #12

From AstraZeneca: > One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. All results were statistically significa…

Wow, what a fascinating phenomenon. A weak first dose somehow primes the immune system better than a full one?

“The thing is, the immune system is very complicated.”

quote from the link here, but for those who don’t want to click through (this article is fascinating though), it is told in the context of a joke which i will post below the link.

https://www.theatlantic.com/health/archive/2020/08/covid-19-...

There’s a joke about immunology, which Jessica Metcalf of Princeton recently told me. An immunologist and a cardiologist are kidnapped. The kidnappers threaten to shoot one of them, but promise to spare whoever has made the greater contribution to humanity. The cardiologist says, “Well, I’ve identified drugs that have saved the lives of millions of people.” Impressed, the kidnappers turn to the immunologist. “What have you done?” they ask. The immunologist says, “The thing is, the immune system is very complicated…” And the cardiologist says, “Just shoot me now.”

Re: Oxford University breakthrough on global COVID-19 vaccine

#27

Post by threeseed »

agd wrote: post #10

I think I read (and I may be wrong) that the costs for the vaccines per dose were roughly as follows: Moderna: £45, Pfizer: £20, Oxford: £3, The Oxford one is also easier to store and transport.

Oxford one is also going to be easier to manufacture given that it is based on existing technology.

Many countries e.g. Australia are licensing the formula so this is an important aspect.

Re: Oxford University breakthrough on global COVID-19 vaccine

#28

Post by acqq »

threeseed wrote: post #21
camkego wrote: post #16

This statement seems a big deal: "There were no hospitalised or severe cases in anyone who received the vaccine" Is that also true of the Pfizer and Moderna trials? Are the various trials measuring 'effectiveness' in the same way? Is there a standard for 'effectiveness' in these Covid-19 trials? It will take some digging and real effort to compare the risks and benefits of the various vaccines coming to market.

There were no hospitalisations or severe incidents for either the Pfizer and Moderna trials were was related to the vaccine. And it's pretty easy to compare the vaccines. It will mostly come down to price, ease of manufacture and ease of distribution i.e. temperature. Given that for the 3 viruses all have no risks associated with their use.

There was one vaccinated but then severe case in Pfizer trial out of 170 cases evaluated where placebo-then-ill cases are included, or 1 from total 8 vaccinated but then ill.

“There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.” (1) “170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group.”

1) https://www.pfizer.com/news/press-release/press-release-deta...

Re: Oxford University breakthrough on global COVID-19 vaccine

#29

Post by MattGaiser »

threeseed wrote: post #21
camkego wrote: post #16

This statement seems a big deal: "There were no hospitalised or severe cases in anyone who received the vaccine" Is that also true of the Pfizer and Moderna trials? Are the various trials measuring 'effectiveness' in the same way? Is there a standard for 'effectiveness' in these Covid-19 trials? It will take some digging and real effort to compare the risks and benefits of the various vaccines coming to market.

There were no hospitalisations or severe incidents for either the Pfizer and Moderna trials were was related to the vaccine. And it's pretty easy to compare the vaccines. It will mostly come down to price, ease of manufacture and ease of distribution i.e. temperature. Given that for the 3 viruses all have no risks associated with their use.

Eh, I think speed to manufacture/distribute is more important. The cost of these is trivial compared to social distancing/lockdown.

Re: Oxford University breakthrough on global COVID-19 vaccine

#30

Post by elric »

threeseed wrote: post #21
camkego wrote: post #16

This statement seems a big deal: "There were no hospitalised or severe cases in anyone who received the vaccine" Is that also true of the Pfizer and Moderna trials? Are the various trials measuring 'effectiveness' in the same way? Is there a standard for 'effectiveness' in these Covid-19 trials? It will take some digging and real effort to compare the risks and benefits of the various vaccines coming to market.

There were no hospitalisations or severe incidents for either the Pfizer and Moderna trials were was related to the vaccine. And it's pretty easy to compare the vaccines. It will mostly come down to price, ease of manufacture and ease of distribution i.e. temperature. Given that for the 3 viruses all have no risks associated with their use.

> There were no hospitalisations or severe for both the Pfizer and Moderna trials that was related to the vaccine.

I think the commenter wanted to know whether anyone who received the vaccine was hospitalized for anything covid related, not for anything vaccine related.

Post reply on HN